CAV1 and diabetic cardiomyopathy: In the context of network pharmacology, five constituents of ZGCD—namely lysine, quercetin, gamma-aminobutyric acid, stigmasterol, and beta-sitosterol—are posited to exert anti-diabetic cardiomyopathy (anti-DCM) effects through interactions with the molecular targets ASS1, SERPINE1, CACNA2D1, AVP, APOB, ICAM1, EGFR, TNNC1, F2, F10, IGF1, TNNI2, CAV1, INSR, and INS.